Clinical bottom line
Pediatric anxiety disorders are common and often underdiagnosed in primary care. Evidence supports the use of brief, validated screening tools combined with stepped-care approaches including psychoeducation, cognitive-behavioral therapy (CBT), and selective pharmacotherapy when indicated. Early identification and integrated behavioral health interventions within primary care settings can improve outcomes and reduce symptom burden.
What the evidence shows
Hilliard et al. (2024) emphasize improved diagnostic strategies for pediatric anxiety disorders, recommending use of validated screening instruments to enhance early detection. They highlight that anxiety symptoms are frequently missed without systematic assessment, underscoring the need for clinician training and structured evaluation.
Petts et al. (2021) review brief screening and intervention strategies feasible in primary care, advocating for integration of behavioral health specialists to deliver evidence-based interventions such as CBT. They note that early, brief interventions can reduce symptom severity and prevent progression.
Pettitt et al. (2022) provide a comprehensive overview of management approaches, supporting psychoeducation and CBT as first-line treatments. Pharmacological options, including selective serotonin reuptake inhibitors (SSRIs), are reserved for moderate to severe cases or when psychotherapy is insufficient or unavailable.
Mian et al. (2020) demonstrate the utility of video-based training modules to enhance primary care providers’ competence in identifying and managing pediatric anxiety, suggesting that targeted education improves provider confidence and adherence to guidelines.
Fuchs et al. (2015) discuss detection and treatment pathways in primary care, emphasizing collaborative care models that integrate mental health professionals to optimize treatment adherence and outcomes.
Manter et al. (2025) address pharmacological management in neurodevelopmental disorders with co-occurring anxiety, highlighting the importance of individualized treatment plans and monitoring for side effects.
Caveats and uncertainty
Screening tools vary in sensitivity and specificity, and false positives may lead to unnecessary referrals or treatment. Access to behavioral health specialists remains limited in many primary care settings, potentially delaying evidence-based interventions.
Pharmacotherapy in pediatric anxiety requires careful risk-benefit assessment, given limited long-term safety data and potential side effects. Family preferences and stigma may also influence treatment acceptance.
There is a paucity of large-scale randomized controlled trials specifically conducted in primary care populations, limiting generalizability of some findings.
How this may change practice
Primary care clinicians should routinely incorporate validated anxiety screening tools during health maintenance visits or when symptoms arise, facilitating early identification.
Embedding behavioral health providers within primary care or establishing strong referral networks can enable timely delivery of CBT and other psychosocial interventions.
Clinicians should engage families in shared decision-making regarding treatment options, balancing psychotherapy and pharmacotherapy based on severity and patient context.
Ongoing provider education, including video-based training, can enhance diagnostic accuracy and management confidence.
Adopting collaborative care models may improve treatment adherence and clinical outcomes for pediatric anxiety disorders.